Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause

Fezolinetant (Veoza, Astellas Pharma) is indicated for 'the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause'.

The dosage schedule is available in the summary of product characteristics for fezolinetant.

The list price for fezolinetant is £44.80 per 28‑tablet pack.

Costs may vary in different settings because of negotiated procurement discounts.

For information, Astellas' Carbon Reduction Plan for UK carbon emissions is published on Astellas' webpage on sustainability.